Eisai is one of the world's leading R&D-based pharmaceutical companies and has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc). Eisai recently expanded their UK Hatfield facility which now supports the company's growing European, Middle Eastern and African (EMEA) business.
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, multiple sclerosis,
neuropathic pain, epilepsy, depression
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc and supportive cancer therapies; pain relief, nausea
- Vascular/Immunological reaction including: acute coronary syndrome,
atherothrombotic disease, rheumatoid arthritis, psoriasis, Crohn's disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, and Belgium.
For further information please visit our web site http://www.eisai.com
About BIAL
Founded in 1924, BIAL is an international pharmaceutical group with products available in more than 40 countries throughout four continents. BIAL is a privately held Portuguese research based pharmaceutical company and the largest Portuguese pharmaceutical company, based in S. Mamede do Coronado, Portugal, responsible for the research and development of eslicarbazepine acetate (Zebinix(R)).
It is the partner of choice for many companies, having a strong presence in the Iberian Peninsula as well as in over 10 countries in Latin America and in around 20 French or Portuguese speaking African countries.
BIAL is strongly committed to therapeutic innovation investing more than 20% of its turnover in research and development every year. Key research areas for BIAL are the central nervous system, the cardiovascular system and allergen immunotherapy. BIAL currently has several other innovative programs under development, which the company expects to bring to the market within the next years, thereby strengthening its position throughout Europe.
Further information about BIAL can be found at http://www.bial.com
References
1. Summary of Product Characteristics Zebinix(R) (eslicarbazepine acetate)(updated
November 2011)
2. Titlic, M. Basic, S. Hajnek, S. Comorbidity psychiatric disorders in epilepsy: a
review of literature. Bratisl Lek Listy (Bratislava Medical Journal) 2009; 110 (2): 105
- 109
3. Epilepsy must become a higher priority in Europe. The Lancet Neurology. 2010 Oct;
9(10): 941
4. Comité National Epilepsie (Last accessed 21.02.2012)
http://www.comite-national-epilepsie.fr
5. Cramer JA, Elger C, Halasz P, et al, editors. An evaluation of quality of life and
depressive symptoms during long-term treatment with eslicarbazepine acetate:
BIA-2093-301 study [abstract 3.197]. American Epilepsy Society Congress; 2008 5-9
December; Seattle, WA.
6. Epilepsy Research UK. What is Epilepsy? Fact sheet. Avaiable from URL:
http://www.epilepsyresearch.org.uk/about... (accessed March
2012)
7. Epilepsy Action. Describing Seizure Types. Avaiable at URL
http://www.epilepsy.org.uk/info/seizures... (Accessed March 2012)
8. NHS Choices. Symptoms of Epilepsy. Available at URL
http://www.nhs.uk/Conditions/Epilepsy/Pa... (Accessed March 2012)
9. Rauchenzauner M, Luef G. Update on the treatment of partial onset epilepsy: a role
of eslicarbazepine. Neurophsyiactric Disease and Treatment. 2010 Nov; 6(1): 723-730
10. Elger C, Halász P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as
adjunctive treatment in adults with refractory partial-onset seizures: A randomized,
double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;
50(3):454-463.
11. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093).
Neurotherapeutics. 2007 Jan;4(1):88-96.
12. Elger et al. Eslicarbazepine Acetate: A Double-blind, Add-on Placebo-controlled
Exploratory Trial in Adult Patients with Partial-onset seizures. Epilepsia,
48(3):497-504, 2007
13. Ben-Menachem E, Gabbai A, Hufnagel A, Maia J, Almeida L, Soares-da-Silver P.
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy;
Epilepsy Research 2010;89:278-285.
14. Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of 800 and 1200 mg
eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset
seizures. Acta Neurol Scand 2009: 120: 281-287.
15. Halász P, Elger C, Guekht A, et al. Long-term efficacy and safety of
eslicarbazepine acetate: Results of a 1-year open-label extension study in
partial-onset seizures in adults with epilepsy. Epilepsia, 18 Abr. (10) - :1963-1969, 2010.
16. Lopes-Lima J, Gil-Nagel A, Maia J, et al. Long-term treatment of partial epilepsy
with eslicarbazepine acetate (ESL): results of a one-year open-label extension of study
BIA-2093-303 (Abstract No. 3.227). Epilepsia. 2008;49(Suppl. 7):441-2.
17. Gabbai A, Ben-Menachem E, Maia J, et al. Long-term treatment of partial epilepsy
with eslicarbazepine acetate (ESL): results of a one-year open-label extension of study
BIA-2093- 302 (Abstract No. 3.208). Epilepsia. 2008;49(Suppl. 7):432-3.
18. Cramer J, Maia J, Almeida L, et al. Quality-of-life improvement during long-term
treatment with eslicarbazepine acetate (Abstract No. T278) Epilepsia 2009:50 (Suppl.
4):123.
CONTACT: Media Enquiries, Eisai Europe Ltd, Cressida Robson, +44-7908-314-155, Cressida_Robson@eisai.net; Tonic Life Communications,Benjamyn Tan / Leah Peyton,+44-(0)207-798-9262, +44-(0)7788-191434,benjamyn.tan@toniclc.com / eisaiepilepsy@toniclc.com
